immuno oncology frontiers world miami


Ed Pezella

Dr Ed Pezella

Former National Medical Director, Pharmacy Policy and Strategy, Aetna

Edmund Pezalla, M.D., MPH, is Aetna’s National Medical Director for Pharmaceutical Policy and Strategy. He is responsible for the integration of pharmacy policy and activities into Aetna’s overall strategy and operations. Dr. Pezalla also serves as the lead clinical spokesperson for Aetna in pharmacy related issues and represents Aetna on industry work groups and conferences.

Dr. Pezalla is Aetna’s leading executive on pharmaceutical development, reimbursement strategy and drug evaluation. He is active on projects with the IOM, CDC and FDA as well as MIT’s Center for Biomedical Innovation.

Dr. Pezalla was an invited expert contributing to the President’s Council of Advisors on Science and Technology report: Propelling Innovation in Drug Discovery, Development and Evaluation. In 2014 Dr. Pezalla served as Aetna’s interim Chief Medical Officer for SEHA, the Qatari National Health Insurance Scheme.

Dr. Pezalla is a graduate of Georgetown University College of Arts and Sciences, and Georgetown University School of Medicine. He holds an MPH from the University of California at Berkeley and was a research fellow and doctoral student in Health Management and Policy at the University of Michigan.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy